Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PIC1 Injection
PIC1 · 1 trial · 1 indication
Types, frequency and severity of adverse events.
| Arm | Type | Description |
|---|---|---|
| PIC1 Injection | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PIC1 Injection | BIOLOGICAL | Three dose groups (1.0×10\^9 TU, 2.0×10\^9 TU, 4.0×10\^9 TU) were set up, starting from the low dose group climbing to explore the safe and effective dose. |
Inclusion Criteria: * The patient (or their legally authorized representative) has voluntarily agreed to participate in this clinical trial and has signed the Informed Consent Form (ICF), indicating full understanding of the study's objectives and procedures. * Aged 18 to 75 years, regardless of ge...
PIC1 is an investigational monoclonal antibody being developed for the treatment of Non-Hodgkin Lymphoma. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma.
PIC1 is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol DTIL. The company is conducting a Phase 1 clinical trial of PIC1 in China for the treatment of Non-Hodgkin Lymphoma.
PIC1 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is recruiting patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma.
PIC1 is being evaluated in a single Phase 1 clinical trial with the identifier NCT07456371. This trial is titled 'PIC1 Injection Therapy for Relapsed/Refractory B-NHL' and is currently recruiting participants in China. The study is an uncontrolled, open-label trial with an enrollment target of 18 patients.
Yes, PIC1 is also known as PIC1 Injection. The drug is administered as an injection and is being studied in a Phase 1 clinical trial for Non-Hodgkin Lymphoma. The alternative name reflects the formulation of the investigational therapy.